Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc

Bullboard Posts

Comment by rickycleanon Apr 30, 2020 9:57am

84 Views

Post# 30970722

RE:Look at the big picture, not just today’s trading

Yes, exactly.

Let's read again the last part of the news to stay clear for the ACTUALITY:

"The Company cautions that while it is preparing to begin a Phase 2 clinical

trial shortly in South Korea and Canada, it is not making any express or

implied claims that NP-120 (Ifenprodil) is an effective treatment for acute lung

injury (ALI), the COVID-19 virus, or any other medical condition at this time."

The company is smart for this precision, but what about also for them to continue the precision and give an idea (just an idea) of a period they calculate they would be near to be able to date when they will be able "to make an express or implied claim" that they sure have an idea actually.

Bullboard Posts

Rich TV Live's Stocks to Watch this week (May 31, 2024)